Pathology

American Liver Foundation Elects New Chair of the Board

Retrieved on: 
Tuesday, March 21, 2023
Fatty liver disease, Medical laboratory, University, ALF, Senior, Leonard M. Miller School of Medicine, Associate professor, Liver disease, Cancer, American Liver Foundation, University of North Carolina at Chapel Hill, Doctor of Philosophy, Bangladesh Technical Education Board, Liver cancer, Hepatitis, MD, Pathology, Patient, Hepatology, Liver, ICU, Viral hepatitis, Science Publishing Group, NIH, Pharmaceutical industry, Medicine

FAIRFIELD, N.J., March 21, 2023 /PRNewswire/ -- Over the weekend at its quarterly meeting, the national board of directors for the American Liver Foundation (ALF) announced the election of a new board chair, Emmanuel Thomas, MD, PhD, FAASLD, Associate Professor, Pathology and Laboratory Medicine at the University of Miami Miller School of Medicine. Dr. Thomas replaces outgoing chair, Daniel Weil of Highwood, Illinois who has served for the past three years. ALF board chairs serve three consecutive one-year terms.

Key Points: 
  • Dr. Thomas replaces outgoing chair, Daniel Weil of Highwood, Illinois who has served for the past three years.
  • "On behalf of the entire board, we are so grateful to Dr. Thomas for his leadership at ALF.
  • "I am honored and humbled to be elected as board chair of an organization that has led the way for liver patients for nearly 47 years," said Dr. Thomas.
  • Before his election as board chair of ALF, Dr. Thomas served the organization as a national board member, medical advisor, and chair of the board nominating committee.

University of Medicine and Health Sciences Celebrates Successful Match Day for Graduating Students

Retrieved on: 
Tuesday, March 21, 2023
UMHS, Perseverance, Mayo Clinic, University, Emergency medicine, Internal medicine, Pediatrics, Thomas Jefferson University, Pathology, Blog, Science, Tulane University, Student, COVID-19, Physician, Match Day (medicine), University of Medicine and Health Sciences, Clinical professor, Psychiatry, Neurology, Anesthesiology, Nursing, Match

NEW YORK, March 21, 2023 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, celebrated the culmination of four years of medical school with one of the most successful Match Days in the school's history. Graduating students secured residencies spanning 11 medical specialties across 24 states and territories, including multiple matches in California, Texas, Michigan, and Puerto Rico, and the school's first matches in Oregon and New Hampshire.

Key Points: 
  • In a message to students, UMHS President Warren Ross celebrated the 2023 Match Results, noting that students secured residencies in highly coveted programs at top-notch teaching hospitals.
  • UMHS students entering this year's Match earned residency positions in primary care specialties spanning internal medicine, family medicine, pediatrics, psychiatry, and surgery, as well as specialized programs including emergency medicine, pathology, anesthesiology, neurology, and diagnostic radiology.
  • "Congratulations to this year's graduates on the best Match Day in our school's history," said Ross.
  • To learn more about the UMHS Class of 2023 Match Day and to see the complete 2023 Match results please visit https://www.umhs-sk.org/match-day-2023 .

Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs

Retrieved on: 
Tuesday, March 21, 2023
GLP, Drug development, Therapy, Toxicology, Research, Patient, Artificial intelligence, R, ChromeOS, Fine chemical, Pathology

LAVAL, Québec and PHILADELPHIA, March 21, 2023 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, today announced that Altasciences, a forward-thinking contract research organization (CRO), has chosen Concentriq® for Research to help its sponsors get life-saving therapeutics to patients sooner. The CRO will deploy Proscia's software platform to advance faster, more complete preclinical development decisions.

Key Points: 
  • The CRO will deploy Proscia's software platform to advance faster, more complete preclinical development decisions.
  • [1] Altasciences is enabling biopharmaceutical companies of all sizes to overcome these lengthy timelines and high costs through its proven approach to preclinical and clinical research and beyond.
  • "Altasciences is an incredibly forward-thinking contract research organization that shares our commitment to innovation," said David West, Proscia's CEO.
  • For a deeper dive into how digitizing its pathology operations with Concentriq for Research will provide value to sponsors worldwide, listen to Altasciences' podcast .

Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria

Retrieved on: 
Tuesday, March 21, 2023
Drug development, Therapy, Parasitism, Climate, Medical laboratory, Kurtis, Ocean Biomedical, RI, CHI3L1, University, World Health Organization, DRS, Research, Doctor of Philosophy, Biology, Glioblastoma, Vaccine, Death, Science, MD, Pathology, Brown University, Parasitemia, Immunology, Artemisinin, Family, Alpert Medical School, NIH, Pharmaceutical industry, Medical device, Malaria, Medicine

Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.

Key Points: 
  • Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.
  • Dr. Elias is Ocean Biomedical’s other Scientific Co-founder and Dean Emeritus of Medicine and Biological Sciences at Brown University.
  • This differential screening technique has led to the discovery of three key targets that are being formulated into a highly effective malaria vaccine candidate being advanced by Dr. Kurtis and Ocean Biomedical.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.

Digital Pathology Service Provider, HistoWiz, Expands Laboratory Footprint to Increase Capacity with New Headquarters in Queens

Retrieved on: 
Monday, March 20, 2023
Research, Science, Histology, Biotechnology, Collaboration, PAS, Pathology, Alexandria Center of Arts, Trichrome staining, Multimedia, H&E, ISH, Hospital, MD, In situ hybridization, Growth

Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.

Key Points: 
  • Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.
  • The HistoWiz laboratory facility houses the Company’s core histology services group including tissue processing, paraffin embedding, sectioning, and staining (H&E, Trichrome, PAS, etc.)
  • and will allow the Company to expand its capabilities in specialty services including immunofluorescence ( IF ) and in situ hybridization ( ISH ).
  • View the full release here: https://www.businesswire.com/news/home/20230320005063/en/
    HistoWiz's new histology lab in Long Island City will increase capacity and turnaround times for customers in biopharma research.

PaxMedica Holds Meeting of Scientific Advisory Board

Retrieved on: 
Monday, March 20, 2023
University of California, San Diego Performance-Based Skills Assessment, Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Suramin, University, Pediatrics, State University of New York Upstate Medical University, Autism spectrum, Spectrum, Baylor University, Coronavirus Scientific Advisory Board, Doctor of Philosophy, Disorder, MD, Pathology, ASD, Behavioural sciences, Baylor College of Medicine, VCU School of Medicine, Pharmaceutical industry, Psychiatry, Medicine

TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.  A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States including:

Key Points: 
  • Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.
    TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.
  • We continue to be very excited about studying a product for the potential treatment of the core symptoms of autism spectrum disorder.”
    Dr. Robert Naviaux added, “At the scientific advisory board meeting this weekend, experts from many different areas of medicine came together to share their thoughts on how suramin may work in ASD and how it might work in several other complex disorders.
  • What emerged was a clear vision for the next steps needed to test suramin in autism.
  • This is expected to be done in a series of international, multicenter, clinical trials that are projected to begin in 2024.”

Proscia Announces Major Expansion In Preclinical R&D To Drive Faster Drug Safety Decisions

Retrieved on: 
Monday, March 20, 2023
GLP, Society, Good laboratory practice, Marie Cassidy, Pathology, Toxicology, Research, H&E, IHC, Organization, Patient, Drug discovery, Immunohistochemistry, Artificial intelligence, Digital, R, ChromeOS, Pharmaceutical industry, Medical imaging, Mobile phone, Fine chemical

PHILADELPHIA, March 20, 2023 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has strengthened its position in the $12 billion[1] preclinical research and development (R&D) market. At the center of its expansion, the company is enhancing its flagship Concentriq® for Research, trusted by 14 of the top 20 pharmaceutical companies as a singular software platform for pathology workflows and data, to accelerate Good Laboratory Practice (GLP) and non-regulated drug safety studies.

Key Points: 
  • Preclinical R&D, which demonstrates if a drug is safe to advance to human clinical trials, centers around workflows with higher volumes of pathology data than any other phase of drug discovery and development.
  • Announced today, Proscia is extending the scalable, intuitive Concentriq for Research to increasingly drive preclinical R&D with new features and services including:
    Robust capabilities for GLP compliance.
  • "These life sciences organizations are making important drug safety decisions that play a key role in getting new therapies to patients.
  • Proscia will also be showcasing the new features during a live webinar on Wednesday, May 3 at 11 AM EDT.

Record-breaking NRMP Match produces 7,132 new DO residents

Retrieved on: 
Friday, March 17, 2023
DOS, Internal medicine, Osteopathic medicine in Canada, American Osteopathic Association, Pediatrics, Pathology, MBA, Medicine, Rehabilitation, Gynaecology, AOA, Otorhinolaryngology, Osteopathy, DO, Student, National Resident Matching Program, NRMP, Patient, Child, Obstetrics, Growth, General surgery, Psychiatry, Neurology, House, Video game, Nursing, Dentistry, Overalls

CHICAGO, March 17, 2023 /PRNewswire/ -- Breaking records from all previous matches, the 2023 National Resident Matching Program (NRMP) matched 7,132 osteopathic medical students and past DO graduates into postgraduate year 1 (PGY1) residency positions. Reaching another all-time high, 91.6% of the 7,436 participating DO students matched into residency programs in 37 specialties.

Key Points: 
  • The American Osteopathic Association (AOA) represents more than 178,000 osteopathic physicians (DOs) and osteopathic medical students.
  • Reaching another all-time high, 91.6% of the 7,436 participating DO students matched into residency programs in 37 specialties.
  • Overall, the number of osteopathic fourth-year students who matched into PGY1 positions increased by 0.3% from last year.
  • This year's Match resulted in increased placements for DO residents in family medicine, internal medicine, and pediatrics.

EQS-News: TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.